Fred Kamal's most recent trade in 4D Molecular Therapeutics Inc was a trade of 260,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Dec. 11, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics Inc | Dr. Fred Kamal, PhD | President and COO | 11 Dec 2023 | 260,000 | 260,000 | - | - | Stock Option (Right to Buy) | ||
| 4D Molecular Therapeutics Inc | Dr. Fred Kamal, PhD | President & COO | 10 Feb 2023 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | ||
| 4D Molecular Therapeutics Inc | Dr. Fred Kamal, PhD | President & COO | 23 Sep 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | ||
| 4D Molecular Therapeutics Inc | Dr. Fred Kamal, PhD | See Remarks | 01 Sep 2022 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | ||
| 4D Molecular Therapeutics Inc | Dr. Fred Kamal, PhD | See Remarks | 01 Feb 2022 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) |